Industry News

Oculus Innovative Sciences, Inc., today announced that the financial results for its fiscal first quarter 2017, ended June 30, 2016, will be released after the U.S. markets close on July 28, 2016. The earnings release will be followed by a conference call at 1:30 p.m. PDT on July 28, 2016, to discuss fiscal first quarter results.. Individuals interested in participating in the conference call may do so by dialing 877-303-7607 for domestic callers or..."/>
Oculus Innovative Sciences Announces Fiscal First Quarter 2017 Financial Results and Conference Call
STELLAR BIOTECHNOLOGIES Inc. today announced the start of their joint venture company, Neostell SAS, with the holding of its first general assembly. At the meeting, the bylaws for Neostell were approved and the Administrative Board and management team were appointed.. The following executives were appointed to the Administrative Board: Bernard Fanget,; Frank Oakes and Miguel Sieler."/>
Neovacs and Stellar Biotechnologies Announce Launch of Neostell, Joint Venture to Manufacture Kinoids
Alexandria Real Estate Equities Inc. plans to beef up its already robust Cambridge life sciences and technology office/lab space portfolio with the $725 million purchase of One Kendall Square. The Pasadena, Calif., real estate investment trust's pending purchase price equates to a hefty $1,124 per square foot for the 7.88- acre, nine-building campus that includes a 1,530- space parking garage and the Kendall Square Cinema in booming East Cambridge."/>
One Kendall Sq. sold [Boston Herald]
Starbucks is expanding the healthcare benefit options it offers employees-- something the company alluded to last week as it announced wage increases and other compensation changes. Currently, Starbucks offers employees three levels of coverage through one insurance company: Blue Cross. Under the new plans, starting Oct. 1 employees can choose between five levels of coverage, provided by carriers including Blue Cross, Aetna, Cigna and UnitedHealthcare."/>
Starbucks expands workers' healthcare choices [The Seattle Times]
Teva Pharmaceutical Industries Ltd. announced today that it successfully priced a debt offering by its special purpose finance subsidiary Teva Pharmaceutical Finance Netherlands III B.V., consisting of the following tranches:. $1.5 billion of 1.400% fixed rate senior notes maturing in 2018; $2.0 billion of 1.700% fixed rate senior notes maturing in 2019; $3.0 billion of 2.200% fixed rate senior notes maturing in 2021; $3.0 billion of 2.800% fixed rate senior notes..."/>
Teva Announces Pricing of $15 Billion of Senior Notes in Connection with Pending Acquisition of Actavis Generics
Cigna's“ Together All The Way” positioning and illustrates how Cigna partners with customers to meet their individual health and wellness needs.. HONG KONG---- Cigna has unveiled its first ever regional brand campaign for key international markets, designed to showcase the company’ s capabilities and the solutions it delivers for customers. The campaign, themed“ All The Way, Means All The Way,” builds on Cigna’ s global wellness mission to..."/>
Cigna Launches Brand Campaign for International Markets Based on Real Stories of Ensuring Customer Health, Well-Being and Security
Insmed, Inc. in the U.S. District Court for the District of New Jersey. The complaint is brought on behalf of all purchasers of Insmed securities between March 18, 2013 and June 8, 2016, for alleged violations of the Securities Exchange Act of 1934 by Insmed's officers and directors."/>
Robbins Arroyo LLP: Insmed, Inc. (INSM) Misled Shareholders According to a Recently Filed Class Action
Cerner campus in south Kansas City finally has a name. Cerner executives settled on Innovations for what has been called the Trails campus located at the former Bannister Mall, near Interstate 435. The name, formally unveiled Monday, stemmed from surveys, focus groups and company input."/>
Cerner offers a glimpse of new south KC campus, unveils its new name [The Kansas City Star]
PRA Health Sciences, Inc. will release its second quarter 2016 results after the market closes on Thursday, July 28. The Company will also host a conference call on Friday, July 29 at 9:00 a.m. to discuss the results with members of the investment community.. To participate via telephone, investors and analysts should dial 930-8062 within the United States or 336-7647 outside the United States approximately 10 minutes prior to the call start time."/>
PRA Health Sciences to Report Second Quarter 2016 Earnings
Haemonetics Corporation today announced that the Company will publish fiscal year 2017 first quarter financial results at 6:00am Eastern Time on Monday, August 1, 2016. The Company will hold a webcast conference call with investors and analysts to discuss and answer questions about the results at 8:00am Eastern Time on August 1, 2016.. Webcast replay will be available from August 1, 2016 after 10:00am Eastern Time."/>
Haemonetics Sets Date for 1st Quarter Fiscal 2017 Earnings Release: August 1, 2016
Gilead Sciences, Inc. announced today that its second quarter 2016 financial results will be released on Monday, July 25, after the market closes. At 4:30 p.m. Eastern Time, Gilead’ s management will host a conference call to discuss the company’ s financial results for the second quarter 2016 and provide a general business update."/>
Gilead Sciences to Release Second Quarter 2016 Financial Results on Monday, July 25, 2016
Arbutus Biopharma Corporation, an industry-leading Hepatitis B Virus therapeutic solutions company, today announced presentation of data on new Lipid Nanoparticle compositions for messenger RNA delivery at the 2016 Controlled Release Society Annual Meeting and..."/>
Arbutus to Present Data on New LNP Formulations for Delivery of mRNA at the 2016 Controlled Release Society Conference
Unilife Corporation today announced that it has submitted its plan to The NASDAQ Stock Market LLC to regain compliance with NASDAQ listing requirements. The Company previously received a letter from NASDAQ notifying the Company that it is not in compliance with NASDAQ Listing Rule 5250 (c) because it has not filed its Form 10- Q for the period ended March 31, 2016 in a timely manner with the Securities and Exchange Commission."/>
Unilife Submits Plan to Regain Compliance with NASDAQ Requirements
Sun Pharmaceutical Industries Ltd on Monday said it has entered into a licensing agreement with Sun Pharma Advanced Research Co. Ltd for the latter's epilepsy drug Elepsia XRTM for the US market. SPARC is the research arm of Sun Pharma, India's largest drug maker. As per the agreement, SPARC will give the licence of Elepsia XRTM or levetiracetam extended-release tablets, as they are generically known, to a wholly-owned subsidiary of Sun Pharma for the US market..."/>
Sun Pharma partners SPARC to market epilepsy drug in US [Mint, New Delhi]
Harvard Bioscience, Inc., a global developer, manufacturer and marketer of a broad range of solutions to advance life science, will announce results for its second quarter 2016 before market trading hours on Thursday, July 28, 2016. A conference call to discuss the company's second quarter 2016 financial results and its operations is scheduled for that same date at 8:30 AM ET. On that call, management may respond to questions from the audience and..."/>
Harvard Bioscience Schedules Second Quarter 2016 Conference Call for July 28 at 8:30 AM ET
SANUWAVE Health, Inc., announced today that the Company will have a podium presentation at the Center for Biofilm Engineering’ s 2016 Biofilm Science and Technology Meeting held at Montana State University in Bozeman, Montana on July 19-21, 2016.. SANUWAVE’ s patented shock wave technology showed very promising results in removing difficult to eradicate medical biofilms created by both Gram-negative and Gram-positive species in tests performed..."/>
SANUWAVE Health to Showcase Its Shock Wave Technology at the 2016 Biofilm Science and Technology Meeting
Axovant Sciences Ltd., a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, announced today that the company will host a symposium and make four poster presentations at the 2016 Alzheimer's Association International Conference being held in Toronto July 24-28.. "Our presence at this year's AAIC highlights our progress towards building a leading pipeline of potential treatments for..."/>
Axovant Sciences Announces Presentations and Sponsored Symposium at the 2016 Alzheimer's Association International Conference
Glaukos Corporation, an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, plans to release second quarter 2016 financial results after the market close on Monday, August 1, 2016. The company’ s management will discuss the results during a conference call and..."/>
Glaukos Corporation to Release Second Quarter 2016 Financial Results after Market Close on August 1
Relypsa, Inc., a biopharmaceutical company, today announced that on July 5, 2016, the compensation committee of the company’ s board of directors granted 2 new employees options to purchase an aggregate of 5,700 shares of the company’ s common stock with a per share exercise price of $20.67, the closing trading price on the grant date, and 2,850 restricted stock units. The stock options and restricted stock units were granted pursuant to the Relypsa,..."/>
Relypsa Announces New Employment Inducement Grants

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Financials854 Articles
Information Technology757 Articles
Consumer Discretionary709 Articles
Industrials548 Articles
Health Care466 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at